Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | TRPC1 | P48995 | 2/20 | 0.67 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.67 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.67 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.67 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 9/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193923 | 0.85 | MAPT (0.77) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL21419596 | 0.84 | TRPC1 (0.68) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL8345184 | 0.83 | TRPC1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL1194642 | 0.83 | TRPC1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL2325526 | 0.82 | MAPT (0.76) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL5533620 | 0.82 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL19692480 | 0.82 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL1814204 | 0.82 | ALDH1A1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL12931795 | 0.81 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL2722465 | 0.81 | TRPC1 (0.64) | MAPTTRPC1TRPC3STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285554-B2 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7247635-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060264430-A1 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. | 2006-11-23 | — | — | US | disclosed |
| US-6958339-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20050234055-A1 | Pyrazole derivative | ASTELLAS PHARMA INC. | 2005-10-20 | — | — | US | disclosed |
| US-6348480-B1 | CALCIUM CHANNEL BLOCKERS AND ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-20010011090-A1 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2001-08-02 | — | — | US | disclosed |
| EP-1024138-A1 | PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234055-A1 | Pyrazole derivative | RYR2, RYR1, NR1I3 | MAPT 3575/4885TRPC1 77/4885TRPC3 6/4885 |
| US-20060264430-A1 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | RYR2, HRH4, RYR1 | MAPT 4277/4885TRPC1 105/4885TRPC3 25/4885 |
| US-20010011090-A1 | Pyrazole derivative | RYR1, CACNA1E, RYR2 | MAPT 3634/4885TRPC1 43/4885TRPC3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.